ASX, Nasdaq and Media Release 8 August 2024 Opthea to Participate in the H.C. Wainwright 4 th Annual Ophthalmology Virtual Conference

ASX, Nasdaq and Media Release

Opthea to Participate in the H.C. Wainwright

4th Annual Ophthalmology Virtual Conference, August 15, 2024

Melbourne, Australia, and Princeton, NJ, US, August 8, 2024-- Opthea Limited (ASX/NASDAQ:OPT, Opthea , the Company ), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4thAnnual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.

Virtual Conference Details:

Presentation: Available on Thursday, August 15, 2024, 7:00 am ET

Presenter: Frederic Guerard, PharmD, CEO Opthea

The webcast will be accessible both via the link: https://journey.ct.events/view/bc8c5e95-651e-4824-bee8-923a1a7479fa and on the Events & Presentations section of Opthea's website at http://ir.opthea.com/.

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.

Authorized for release to ASX by Fred Guerard, PharmD, CEO, Opthea